Follow Yahoo News

FILE-In this Monday, Feb. 6, 2012, file photo, Alexis McKenzie, right, executive director of The Methodist Home of the District of Columbia Forest Side, an Alzheimer's assisted-living facility, laughs with resident Catherine Peake, in Washington. Combined results released, Monday, Oct. 8, 2012, from two studies of an experimental Alzheimer's drug under development by Eli Lilly & Co. called solanezumab, suggest that it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies missed their main goals to significantly slow the mind-robbing disease. But pooled results found 34 percent less decline in mild Alzheimer's patients compared to those on a dummy treatment for 18 months. (AP Photo/Charles Dharapak)

FILE-In this Monday, Feb. 6, 2012, file photo, Alexis McKenzie, right, executive director of The Methodist Home of the District of Columbia Forest Side, an Alzheimer's assisted-living facility, laughs with resident Catherine Peake, in Washington. Combined results released, Monday, Oct. 8, 2012, from two studies of an experimental Alzheimer's drug under development by Eli Lilly & Co. called solanezumab, suggest that it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies missed their main goals to significantly slow the mind-robbing disease. But pooled results found 34 percent less decline in mild Alzheimer's patients compared to those on a dummy treatment for 18 months. (AP Photo/Charles Dharapak)